Voloridge Investment Management LLC lowered its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 36.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 183,899 shares of the company's stock after selling 106,132 shares during the period. Voloridge Investment Management LLC owned approximately 0.40% of 4D Molecular Therapeutics worth $1,024,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Peapod Lane Capital LLC bought a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $806,000. Rhumbline Advisers increased its holdings in shares of 4D Molecular Therapeutics by 5.3% during the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock worth $409,000 after purchasing an additional 3,675 shares during the period. Proficio Capital Partners LLC increased its holdings in shares of 4D Molecular Therapeutics by 100.0% during the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock worth $111,000 after purchasing an additional 10,000 shares during the period. M&T Bank Corp increased its holdings in shares of 4D Molecular Therapeutics by 98.9% during the fourth quarter. M&T Bank Corp now owns 37,487 shares of the company's stock worth $209,000 after purchasing an additional 18,639 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $629,000. Institutional investors and hedge funds own 99.27% of the company's stock.
4D Molecular Therapeutics Trading Up 2.8%
Shares of NASDAQ:FDMT traded up $0.10 during mid-day trading on Monday, reaching $3.72. The stock had a trading volume of 228,317 shares, compared to its average volume of 831,214. The company has a market cap of $172.33 million, a P/E ratio of -1.31 and a beta of 2.87. The business's 50 day moving average price is $3.23 and its 200 day moving average price is $4.76. 4D Molecular Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $28.93.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). Analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on FDMT shares. Bank of America reduced their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. The Goldman Sachs Group cut their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Weiss Ratings restated a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a report on Saturday, May 24th. Barclays decreased their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright reissued a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $29.56.
View Our Latest Stock Analysis on FDMT
4D Molecular Therapeutics Company Profile
(
Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Further Reading
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
